Page 188 - Drug Class Review
P. 188
Page 124 of 205
Drug Effectiveness Review Project
placebo 72.6 61 94% 4% 2% 19.2
Groups similar at baseline: No; mean age of DON 10 mg/d group was 2 years older than
donepezil 10mg 74.6 62 96% 2% 3% 18.9 5 mg/d DON-treated patients showed significant improvement in QOL score compared to placebo at week-24 (P < 0.05); no statistically significant differences for DON 10 mg/d 5 mg/d and 10mg/d DON-treated patients had significantly less ADAS-Cog deterioration than placebo at 24 weeks (mean difference of -2.49 and -2.88, respectively; P < 0.0001)* 5 mg/d and 10 mg/d DON-treated patients had significantly better CIBIC-plus scores than placebo at 24 weeks (mean difference of 0.36 and 0.44, respectively; P < 0.005)* 5 mg/d and
placebo (P = 0.03) Alzheimer classification: Mild-moderate donepezil 5mg 72.9 63 95% 3% 2% 19.0 Primary Outcome Measures: ADAS-Cog; CIBIC-plus Secondary Outcome Measures: MMSE; QOL; CDR-SB Timing of assessments: Baseline and every 6 weeks Health Outcome Measures: • Intermediate Outcome Measures: • • • •
Final Report Update 1 Authors: Rogers et al. Year: 1998 POPULATION CHARACTERISTICS: Mean age (years): Sex (% female): Ethnicity: White • Black • Other • Other germane population qualities: Mean baseline MMSE • OUTCOME ASSESSMENT: RESULTS: Alzheimer's Drugs
